Clinical trials: sponsored by Henan Cancer Hospital
Mantle Cell Lymphoma (MCL)
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
This prospective, open-label, phase 2 study will evaluate the efficacy and safety of lisaftoclax in combination with pirtobrutinib in adults with relapsed or refractory mantle cell lymphoma following failure of prior BTK-targeted…
- Trial name
- NCT07684950
- Testing
- Lisaftoclax, Pirtobrutinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Henan Cancer Hospital
HCC - Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
This study aims to explore the value of the 'HAIC Apatinib Camrelizumab' triple regimen for perioperative treatment of resectable hepatocellular carcinoma.
- Trial name
- NCT07618546
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC
- Volunteers
- 208 people
- Sponsor
- Henan Cancer Hospital
Gastric Adenocarcinoma
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
This is a prospective, single-arm, investigator-initiated phase II clinical study. The study evaluates the efficacy and safety of retlirafusp alfa (a PD-L1/TGF-βRII bifunctional fusion protein) combined with apatinib (a VEGFR-2…
- Trial name
- RA-A-NP (NCT07610629)
- Testing
- Retlirafusp alfa + Apatinib + Nab-paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Leptomeningeal Metastasis From Lung Cancer
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
This is a phase I/II, single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, and preliminary efficacy of intrathecal injection of methotrexate-loaded autologous tumor cell-derived…
- Trial name
- NCT07559097
- Testing
- Methotrexate-loaded vesicles
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Henan Cancer Hospital
Advanced Breast Cancer
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
To evaluate the efficacy and safety of toripalimab in combination with investigator-selected chemotherapy in patients with recurrent or metastatic HER2-negative breast cancer who have failed prior systemic therapy.
- Trial name
- 2025-370 (NCT07540533)
- Testing
- Toripalimab, TPC
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Henan Cancer Hospital
HER-2 Negative Breast Cancer
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.
- Trial name
- NCT05398861
- Testing
- utidelone injection, Bevacizumab
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Henan Cancer Hospital
Marginal Zone Lymphoma
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients…
- Trial name
- NCT04433156
- Testing
- Bortezomib, Rituximab, Epirubicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Henan Cancer Hospital
SCLC, Extensive Stage
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of…
- Trial name
- NCT04660097
- Testing
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer
This study now plans to explore the efficacy and safety of hetrombopag in cancer therapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced…
- Trial name
- NCT05394285
- Testing
- Hetrombopag
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Metastatic Breast Cancer
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.
- Trial name
- NCT05769010
- Testing
- SHR-A1811, Pyrotinib, Bevacizumab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Henan Cancer Hospital
MZL
CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
This is a multicenter, real-world study on first-line CD20 monoclonal antibody-based regimens for treatment-naive marginal zone B-cell lymphoma based on risk stratification.
- Trial name
- NCT07492407
- Testing
- R2/BR/OR2
- Volunteers
- 131 people
- Sponsor
- Henan Cancer Hospital
DLBCL - Diffuse Large B Cell Lymphoma
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
This is a prospective, observational, non-interventional real-world study that will not alter participants' routine clinical care. Approximately 20 eligible patients with diffuse large B-cell lymphoma (DLBCL) will be enrolled.
- Trial name
- NCT07472621
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer
A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron
This study aims to evaluate the efficacy and safety of a combination regimen based on Rolapitant Palonosetron injection for preventing nausea and vomiting induced by concurrent chemoradiotherapy in lung cancer patients.
- Trial name
- NCT07442890
- Testing
- Rolapitant Palonosetron, Dexamethasone, Olanzapine
- Volunteers
- 238 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
This is a single-center, randomized, open-label, phase II interventional study. Eligible patients will be randomized 1:1 to receive either Trastuzumab-rezetecan (4.8 mg/kg Q3W) or T-DXd (5.4 mg/kg Q3W) for 8 neoadjuvant cycles.
- Trial name
- NCT07416253
- Testing
- Trastuzumab rezetecan, Trastuzumab deruxtecan
- Volunteers
- 68 people
- Sponsor
- Henan Cancer Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage
Anlotinib in Cross-line Treatment of NSCLC and SCLC
Previous studies on bevacizumab in colorectal and ovarian cancers have demonstrated that continued anti-angiogenic therapy after disease progression can still provide clinical benefits.
- Trial name
- NSCLC SCLC (NCT07400575)
- Volunteers
- 350 people
- Sponsor
- Henan Cancer Hospital
Classical Hodgkin Lymphoma
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
This is a prospective single-arm, multi-center and phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.
- Trial name
- NCT04067037
- Testing
- Camrelizumab, Epirubicin, Vincristine
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis of non-small cell lung cancer(NSCLC), 40…
- Trial name
- NCT06370416
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
HCC - Hepatocellular Carcinoma
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
For HCC patients with PVTT who the researchers believe can benefit from radiotherapy combined with tislelizumab and anlotinib, informed consent forms will be signed, and then they will receive the study treatment and be followed…
- Trial name
- NCT07363512
- Testing
- Radiotherapy combined with tislelizumab and anlotinib
- Volunteers
- 27 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial
This study is a prospective, multicenter, multi-cohort Phase III clinical trial. It primarily enrolls high-risk recurrent esophageal cancer patients who have undergone R0 resection after neoadjuvant chemoimmunotherapy.
- Trial name
- NCT07332221
- Testing
- Toripalimab monotherapy
- Volunteers
- 435 people
- Sponsor
- Henan Cancer Hospital
Gastric Adenocarcinoma, Gastric (Stomach) Cancer
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Conditions
- Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
- Trial name
- NCT07334431
- Testing
- fruquintinib＋trastuzumab + XELOX
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Henan Cancer Hospital